QualityStocks would like to highlight Echo Therapeutics (NASDAQ: ECTE). The company is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.
In the company’s news last week,
Echo Therapeutics announced the issuance of patents covering its Prelude® SkinPrep System for transdermal drug delivery, as well as a notice of allowance for a patent for its Symphony® tCGM System, a non-invasive, wireless, transdermal continuous glucose monitoring system.
Patent approval extends the company’s current patent portfolio, which is comprised of six U.S. patents; more than 60 foreign patents; and more than 30 patent applications pending, both in the U.S. and abroad.
“The issuance of these patents further broadens Echo’s already extensive intellectual property portfolio surrounding Prelude and Symphony and represents a valuable asset for Echo,” Patrick Mooney, M.D., Echo’s chairman and CEO stated in the press release. “Furthermore, we expect additional U.S. and foreign patents to issue this year that will provide our products with long-term market value and will add significantly to our shareholder value.”
The company’s patents, entitled “Skin Permeation Device for Analyte Sensing or Transdermal Drug Delivery,” are issued in Australia, Hong Kong, New Zealand, Russia, and 34 European countries, and include claims that encompass the Prelude SkinPrep System. These patents are set to expire in 2028.
The company also received a notice of allowance for U.S. patent application entitled “System and Method for Analyte Sampling and Analysis with Hydrogel.” The patent, when issued, is expected to expire in 2026.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
